6,678 trials
Cervical Intraepithelial Neoplasia
Primary: Number of Subjects With Serious Adverse Events (SAEs) Related to Study Vaccine in Vacc-092 Group — 0 Participants
Chronic Rhinosinusitis (Diagnosis) · Allergic Rhinosinusitis · Chronic Eosinophilic Rhinosinusitis
Primary: Change in Sino-Nasal Outcome Test Scores (SNOT-22) — 23.18; 17.7 score on a scale
Skin Wrinkling
Primary: Horizontal Diameter of the Fields of Anhidrotic Effect — 0.84; 1.24 centimeters
Influenza
Primary: Number of Participants Aged 6 Months to < 9 Years Who Provided Serum Samples for Analysis: Groups 1 and 2 — 28; 30; 22; 28 Participants
Male Infertility
Primary: Pain Scores 48 Hours After Surgery — 118.4; 98.2 Scores*Hour — p=0.41
Cervical Cancer · Hpv · Warts
Primary: Number of Subjects Showing Seroconversion to All HPV Four Serotypes — 9 Participants
Acne Rosacea
Primary: IGA (Investigator Global Assessment) — 54; 4 Participants
Schizophrenia · Schizoaffective Disorder
Primary: Overall Cognitive Improvement Z-score — 0.03; -0.03; 0.15; 0.61 z-score — p=<0.05
Medication Adherence
Primary: Medication Adherence — 85.36; 86.79; 81.93; 86.09 Percentage
Post Operative Pain (Post Laparoscopic Hernia Repair)
Primary: Visual Analog Scale Pain Score Assessment (VAS) — 2.96; 3.24 score on a scale
Parenteral Nutrition Associated Liver Disease
Primary: Number of Participants With Resolution of the Direct Hyperbilirubinemia — 29 Participants
Chronic Obstructive Pulmonary Disease
Primary: Percentage of Patients With a Positive Treatment Response — 97; 82 Participants — p=0.0422
Pain
Primary: Area Under The Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores From 12 to 48 Hours — 181.523; 208.407 cm*hr — p=0.0381
Actinic Keratoses
Primary: Overall Subject Satisfaction the Day of Treatment After Daylight Session — 47 Participants
Postoperative Pain
Primary: Milligrams of Intravenous Morphine Used by Participant in First 24 Hours Postoperatively — 18; 14; 15 Milligrams